Enanta Pharmaceuticals, Inc. (FRA:9EP)

Enanta Pharmaceuticals Statistics

Total Valuation

FRA:9EP has a market cap or net worth of EUR 332.77 million. The enterprise value is 291.42 million.

Market Cap	332.77M
Enterprise Value	291.42M

Important Dates

The last earnings date was Monday, February 9, 2026.

Earnings Date	Feb 9, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	29.02M
Shares Outstanding	n/a
Shares Change (YoY)	+9.53%
Shares Change (QoQ)	+34.46%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	20.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.83
PB Ratio	3.09
P/TBV Ratio	3.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.78
EV / Sales	5.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.53

Financial Position

The company has a current ratio of 4.44, with a Debt / Equity ratio of 1.53.

Current Ratio	4.44
Quick Ratio	4.34
Debt / Equity	1.53
Debt / EBITDA	n/a
Debt / FCF	-10.46
Interest Coverage	-8.30

Financial Efficiency

Return on equity (ROE) is -60.01% and return on invested capital (ROIC) is -69.31%.

Return on Equity (ROE)	-60.01%
Return on Assets (ROA)	-13.47%
Return on Invested Capital (ROIC)	-69.31%
Return on Capital Employed (ROCE)	-25.65%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	475,391
Profits Per Employee	-507,734
Employee Count	120
Asset Turnover	0.20
Inventory Turnover	n/a

Taxes

Income Tax	-1.04M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +47.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+47.77%
50-Day Moving Average	11.58
200-Day Moving Average	8.54
Relative Strength Index (RSI)	49.00
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.74

Income Statement

In the last 12 months, FRA:9EP had revenue of EUR 57.05 million and -60.93 million in losses. Loss per share was -2.62.

Revenue	57.05M
Gross Profit	57.05M
Operating Income	-62.22M
Pretax Income	-61.97M
Net Income	-60.93M
EBITDA	-58.03M
EBIT	-62.22M
Loss Per Share	-2.62

Balance Sheet

The company has 158.29 million in cash and 164.53 million in debt, with a net cash position of 41.50 million.

Cash & Cash Equivalents	158.29M
Total Debt	164.53M
Net Cash	41.50M
Net Cash Per Share	n/a
Equity (Book Value)	107.82M
Book Value Per Share	3.72
Working Capital	131.12M

Cash Flow

In the last 12 months, operating cash flow was -12.07 million and capital expenditures -3.66 million, giving a free cash flow of -15.73 million.

Operating Cash Flow	-12.07M
Capital Expenditures	-3.66M
Free Cash Flow	-15.73M
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of -109.08% and -106.80%.

Gross Margin	100.00%
Operating Margin	-109.08%
Pretax Margin	-108.62%
Profit Margin	-106.80%
EBITDA Margin	-101.72%
EBIT Margin	-109.08%
FCF Margin	n/a

Dividends & Yields

FRA:9EP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.53%
Shareholder Yield	-9.53%
Earnings Yield	-18.31%
FCF Yield	-4.73%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:9EP has an Altman Z-Score of -1.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.15
Piotroski F-Score	3